AstraZeneca can now sell its cancer drug in India
What's the story
AstraZeneca Pharma India Ltd has received the nod from the Central Drugs Standard Control Organisation (CDSCO) to import and sell a cancer treatment drug called Durvalumab.
The CDSCO is an agency of the Directorate General of Health Services, under the Government of India.
The endorsement is specifically for the sale and distribution of two variants of Durvalumab solution: 120mg/2.4ml and 500mg/10ml (also called Imfinzi).
Treatment combination
Durvalumab is used in combination with Tremelimumab
The drug Durvalumab, when used in combination with Tremelimumab, is approved for the treatment of patients suffering from unresectable hepatocellular carcinoma (uHCC).
With this new approval, AstraZeneca can market the infusion solution of Durvalumab for this particular additional use in India.
However, this is subject to obtaining all necessary statutory approvals required for the same.
Disease
What is uHCC?
Unresectable hepatocellular carcinoma is a type of liver cancer in which the tumor cannot be removed via surgery. This can be due to the size of the tumor, its location, or even the spread of cancer.